Skip to main content

Advertisement

SpringerLink
Log in

Antitumor effect of non-steroid glucocorticoid receptor ligand CpdA on leukemia cell lines CEM and K562

  • Published:
Biochemistry (Moscow) Aims and scope Submit manuscript

Abstract

Glucocorticoids (GCs) are widely used in chemotherapy of hematological malignancies, particularly leukemia. Their effect is mediated by glucocorticoid receptor (GR), a well-known transcription factor. Besides their therapeutic impact, GCs may cause a number of side effects leading to various metabolic complications. The goal of immediate interest is testing glucocorticoid analogs capable of induction/enhancement of GR transrepression, but preventing GR dimerization and transactivation leading to side effects. In this work we have investigated effects of a promising new selective GR agonist, 2-(4-acetoxyphenyl)-2-chloro-N-methylethylammonium chloride (CpdA), on CEM and K562 leukemia cells. Both cell lines express functional GR. CpdA compared with the glucocorticoid fluocinolone acetonide (FA) exerted more prominent cytostatic and apoptotic effects on the cells. Both cell lines exhibited sensitivity to CpdA, demonstrating a good correlation with the effects of FA on cell growth and viability. In contrast to FA, CpdA did not induce GR transactivation evaluated by no obvious increase in expression of GR target (and dependent) gene FKBP51. At the same time, luciferase assay showed that CpdA efficiently activated transrepression of NF-ϰB and AP-1 factors. We also evaluated the effect of combined action of CpdA and the proteasome inhibitor Bortezomib. The latter induced a caspase-dependent apoptosis in both T-cell leukemia cell lines. By treatment of CEM cells with different CpdA/GC and Bortezomib doses, we have designed a protocol where CpdA shows potentiating effect on Bortezomib cytotoxic activity. Generally, the present work characterizes a novel non-steroid GR ligand, CpdA, as a promising compound for possible application in leukemia chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

CpdA:

2-(4-acetoxyphenyl)-2-chloro-N-methylethylammonium chloride

DMSO:

dimethyl sulfoxide

ER:

endoplasmic reticulum

FA:

fluocinolone acetonide

GAPDH:

glyceraldehyde-3-phosphate dehydrogenase

GC:

glucocorticoid

GR:

glucocorticoid receptor

HDAC-1:

histone deacetylase-1

PARP:

poly(ADP-ribose) polymerase

PI:

propidium iodide

SEGRA:

selective GR agonist

References

  1. Adcock, I. M. (2000) Pulm. Pharm. Ther., 13, 115–126.

    Article  CAS  Google Scholar 

  2. Chebotaev, D., Yemelyanov, A., and Budunova, I. (2007) Mol. Carcinog., 46, 732–740.

    Article  PubMed  CAS  Google Scholar 

  3. Rehwinkel, H., and Schacke, H. (2006) Chem. Med. Chem., 1, 803–805.

    PubMed  CAS  Google Scholar 

  4. Schacke, H., Berger, M., Rehwinkel, H., and Asadullah, K. (2007) Mol. Cell Endocrinol., 275, 109–117.

    Article  PubMed  Google Scholar 

  5. Yemelyanov, A., Czwornog, J., Chebotaev, D., Karseladze, A., Kulevitch, E., Yang, X., and Budunova, I. (2007) Oncogene, 26, 1885–1896.

    Article  PubMed  CAS  Google Scholar 

  6. Louw, A., and Swart, P. (1999) Endocrinology, 140, 2044–2053.

    Article  PubMed  CAS  Google Scholar 

  7. Yemelyanov, A., Czwornog, J., Gera, L., Joshi, S., Chatterton, R. T., Jr., and Budunova, I. (2008) Cancer Res., 68, 4763–4773.

    Article  PubMed  CAS  Google Scholar 

  8. De Bosscher, K., Vanden Berghe, W., Beck, I. M. E., van Molle, W., Hennuyer, N., Hapgood, J., Libert, C., Staels, B., Louw, A., and Haegeman, G. (2005) Proc. Natl. Acad. Sci. USA, 102, 15827–15832.

    Article  PubMed  Google Scholar 

  9. Dewint, P., Gossye, V., de Bosscher, K., Vanden Berghe, W., Muller-Ladner, U., Vander Cruyssen, B., Haegeman, G., and Elewaut, D. (2008) J. Immunol., 180, 2608–2615.

    PubMed  CAS  Google Scholar 

  10. Orlowski, R. Z., Stinchcombe, T. E., Mitchell, B. S., Shea, T. C., Baldwin, A. S., Stahl, S., Adams, J., Esseltine, D. L., Elliott, P. J., Pien, C. S., Guerciolini, R., Anderson, J. K., Depcik-Smith, N. D., Bhagat, R., Lehman, M. J., Novick, S. C., O’Connor, O. A., and Soignet, S. L. (2002) J. Clin. Oncol., 20, 4420–4427.

    Article  PubMed  CAS  Google Scholar 

  11. McConkey, D. J., and Zhu, K. (2008) Drug Resist., 11, 164–179.

    Article  CAS  Google Scholar 

  12. Romaguera, J. E., Fayad, L. E., McLaughlin, P., Pro, B., Rodriguez, A., Wang, M., Weaver, P., Hartig, K., Kwak, L. W., Feldman, T., Smith, J., Ford, P., Goldberg, S., Pecora, A., and Goy, A. (2010) Br. J. Haematol., 151, 47–53.

    Article  PubMed  CAS  Google Scholar 

  13. Messinger, Y., Gaynon, P., Raetz, E., Hutchinson, R., Dubois, S., Glade-Bender, J., Sposto, R., van der Giessen, J., Eckroth, E., and Bostrom, B. C. (2010) Pediatr. Blood Cancer, 55, 254–259.

    Article  PubMed  Google Scholar 

  14. Elliott, P. J., Zollner, T. M., and Boehncke, W.-H. (2003) J. Mol. Med., 81, 235–245.

    PubMed  CAS  Google Scholar 

  15. Yu, C., Rahmani, M., Conrad, D., Subler, M., Dent, P., and Grant, S. (2003) Blood, 102, 3765–3774.

    Article  PubMed  CAS  Google Scholar 

  16. Cusack, J. C., Jr., Liu, R., Houston, M., Abendroth, K., Elliott, P. J., Adams, J., and Baldwin, A. S., Jr. (2001) Cancer Res., 61, 3535–3540.

    PubMed  CAS  Google Scholar 

  17. Kraus, M., Malenke, E., Gogel, J., Muller, H., Ruckrich, T., Overkleeft, H., Ovaa, H., Koscielniak, E., Hartmann, J. T., and Driessen, C. (2008) Mol. Cancer Ther., 7, 1940–1948.

    Article  PubMed  CAS  Google Scholar 

  18. Horton, T. M., Gannavarapu, A., Blaney, S. M., D’Argenio, D. Z., Plon, S. E., and Berg, S. L. (2006) Cancer Chemother. Pharmacol., 58, 13–23.

    Article  PubMed  CAS  Google Scholar 

  19. Rosenberg, I. M. (1996) Protein Analysis and Purification Benchtop Techniques, Birkhauser, Boston, MA.

    Google Scholar 

  20. Verma, R. P. (2006) Anticancer Agents Med. Chem., 6, 489–499.

    Article  PubMed  CAS  Google Scholar 

  21. Miller, A. L., Garza, A. S., Johnson, B. H., and Thompson, E. B. (2007) Cancer Cell. Int., 7, 3.

    Article  PubMed  Google Scholar 

  22. Foley, G. E., Lazarus, H., Farber, S., Uzman, B. G., Boone, B. A., and McCarthy, R. E. (1965) Cancer, 18, 522–529.

    Article  PubMed  CAS  Google Scholar 

  23. Norman, M. R., and Thompson, E. B. (1977) Cancer Res., 37, 3785–3791.

    PubMed  CAS  Google Scholar 

  24. Klein, E., Ben-Bassat, H., Neumann, H., Ralph, P., Zeuthen, J., Polliack, A., and Vanky, F. (1976) Int. J. Cancer, 18, 421–431.

    Article  PubMed  CAS  Google Scholar 

  25. Mihailovic, T., Marx, M., Auer, A., van Lint, J., Schmid, M., Weber, C., and Seufferlein, T. (2004) Cancer Res., 64, 8939–8944.

    Article  PubMed  CAS  Google Scholar 

  26. Van Etten, R. (2007) J. Exp. Med., 204, 461–465.

    Article  PubMed  Google Scholar 

  27. Tefferi, A., and Vardiman, J. W. (2007) Curr. Opin. Hematol., 14, 115–122.

    Article  PubMed  Google Scholar 

  28. Chiaretti, S., and Foa, R. (2009) Haematologica, 94, 160–162.

    Article  PubMed  CAS  Google Scholar 

  29. Agius, C., and Gidari, A. S. (1982) J. Lab. Clin. Med., 100, 178–185.

    PubMed  CAS  Google Scholar 

  30. Schmidt, S., Irving, J. A., Minto, L., Matheson, E., Nicholson, L., Ploner, A., Parson, W., Kofler, A., Amort, M., Erdel, M., Hall, A., and Kofler, R. (2006) FASEB J., 20, 2600–2602.

    Article  PubMed  CAS  Google Scholar 

  31. Ramos, R. A., Meilandt, W. J., Wang, E. C., and Firestone, G. L. (1999) FASEB J., 13, 169–180.

    PubMed  CAS  Google Scholar 

  32. Ruiz, M., Lind, U., Gafvels, M., Eggertsen, G., Carlstedt-Duke, J., Nilsson, L., Holtmann, M., Stierna, P., Wikstrom, A. C., and Werner, S. (2001) Clin. Endocrinol. (Oxf.), 55, 363–371.

    Article  CAS  Google Scholar 

  33. Beesley, A. H., Weller, R. E., Senanayake, S., Welch, M., and Kees, U. R. (2009) Leuk. Res., 33, 321–325.

    Article  PubMed  CAS  Google Scholar 

  34. Irving, J. A., Minto, L., Bailey, S., and Hall, A. G. (2005) Cancer Res., 65, 9712–9718.

    Article  PubMed  CAS  Google Scholar 

  35. Kester, H. A., van der Leede, B. M., van der Saag, P. T., and van der Burg, B. (1997) J. Biol. Chem., 272, 16637–16643.

    Article  PubMed  CAS  Google Scholar 

  36. Wallace, A. D., and Cidlowski, J. A. (2001) J. Biol. Chem., 276, 42714–42721.

    Article  PubMed  CAS  Google Scholar 

  37. Chen, D. W., Lynch, J. T., Demonacos, C., Krstic-Demonacos, M., and Schwartz, J. M. (2010) Pharmaco-genomics, 11, 1545–1560.

    CAS  Google Scholar 

  38. Gossye, V., Elewaut, D., van Beneden, K., Dewint, P., Haegeman, G., and de Bosscher, K. (2010) Ann. Rheum. Dis., 69, 291–296.

    Article  PubMed  CAS  Google Scholar 

  39. Lee, W., Mitchell, P., and Tjian, R. (1987) Cell, 49, 741–752.

    Article  PubMed  CAS  Google Scholar 

  40. Chen, L., Glover, J. N. M., Hogan, P. G., Rao, A., and Harrison, S. C. (1998) Nature, 392, 42–48.

    Article  PubMed  CAS  Google Scholar 

  41. Miller, A. L., Webb, M. S., Copik, A. J., Wang, Y., Johnson, B. H., Kumar, R., and Thompson, E. B. (2005) Mol. Endocrinol., 19, 1569–1583.

    Article  PubMed  CAS  Google Scholar 

  42. Gossye, V., Elewaut, D., Bougarne, N., Bracke, D., van Calenbergh, S., Haegeman, G., and de Bosscher, K. (2009) Arthritis Rheum., 60, 3241–3250.

    Article  PubMed  CAS  Google Scholar 

  43. Hartmann, B. L., Geley, S., and Kofler, R. (1999) Wien Klin. Wochenschr., 111, 360–367.

    PubMed  CAS  Google Scholar 

  44. Tripathi, P., and Aggarwal, A. (2006) Curr. Sci., 90, 519–531.

    CAS  Google Scholar 

  45. Hermoso, M. A., and Cidlowski, J. A. (2003) IUBMB Life, 55, 497–504.

    Article  PubMed  CAS  Google Scholar 

  46. Hernandez-Espinosa, D., Minano, A., Ordonez, A., Mota, R., Martinez-Martinez, I., Vicente, V., and Corral, J. (2009) J. Thromb. Haemost., 7, 1128–1133.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Carcinogenesis, Blokhin Cancer Research Center, Russian Academy of Medical Sciences, Kashirskoe Shosse 24, 115478, Moscow, Russia

    E. A. Lesovaya, K. I. Kirsanov & M. G. Yakubovskaya

  2. Feinberg Medical School, Department of Dermatology, Northwestern University, Chicago, Illinois, 60611-3008, USA

    A. Yu. Yemelyanov & I. V. Budunova

Authors
  1. E. A. Lesovaya
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Yu. Yemelyanov
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K. I. Kirsanov
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. G. Yakubovskaya
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. I. V. Budunova
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. A. Lesovaya.

Additional information

Original Russian Text © E. A. Lesovaya, A. Yu. Yemelyanov, K. I. Kirsanov, M. G. Yakubovskaya, I. V. Budunova, 2011, published in Biokhimiya, 2011, Vol. 76, No. 11, pp. 1542–1555.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lesovaya, E.A., Yemelyanov, A.Y., Kirsanov, K.I. et al. Antitumor effect of non-steroid glucocorticoid receptor ligand CpdA on leukemia cell lines CEM and K562. Biochemistry Moscow 76, 1242–1252 (2011). https://doi.org/10.1134/S000629791111006X

Download citation

  • Received:

  • Revised:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1134/S000629791111006X

Key words

Search

Navigation